|Articles|March 23, 2004

WCPM 2004 Brochure

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Pharmaceutical Executive Daily: FDA Approves Datroway

ByNicholas Jacobus

May 22nd 2026

FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

ByNicholas Jacobus

May 22nd 2026

Director of NIH Infectious Disease Institute Steps Down

ByMike Hollan

May 22nd 2026

The Biotech Industry’s Relationship with Real-Time Data: Q&A with Dr. Richard Graham

ByMike Hollan,Dr. Richard Graham

May 22nd 2026

Modern Communication Between FDA, Biotech, and Investors: Q&A with David Crean

ByMike Hollan,David Crean

May 22nd 2026

WCPM 2004 Brochure

Related Content

Pharmaceutical Executive Daily: FDA Approves Datroway

FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

Director of NIH Infectious Disease Institute Steps Down

The Biotech Industry’s Relationship with Real-Time Data: Q&A with Dr. Richard Graham

Modern Communication Between FDA, Biotech, and Investors: Q&A with David Crean

Trending on PharmExec

Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report

The Evolving Relationship Between FDA and Biotech

Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio

FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

Pharmaceutical Executive Daily: FDA Approves Datroway